Phase IB pharmacokinetic (PK) study of Src kinase inhibitor AZD0530 plus anastrozole in postmenopausal hormone receptor positive (HR plus ) metatatic breast cancer (MBC)

被引：3
|
作者：
Pegram, M. D.
Silva, O. E.
Higgins, C.
Tukia, K.
Stuart, M.
Slingerland, J.
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[2] Univ Miami, Miami, FL USA
[3] AstraZeneca, Aderley Pk, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e13074
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13074
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Src Kinase Inhibition with AZD0530 Plus Anastrozole in Postmenopausal Hormone Receptor Positive (HR plus ) Metastatic Breast Cancer (MBC)
    Pegram, M.
    Silva, O.
    Higgins, C.
    Tukia, K.
    Avisar, E.
    Stuart, M.
    Slingerland, J.
    [J]. CANCER RESEARCH, 2010, 70
  • [2] Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
    Oswald, Ailsa J.
    Symeonides, Stefan N.
    Wheatley, Duncan
    Chan, Stephen
    Brunt, Adrian Murray
    McAdam, Karen
    Schmid, Peter
    Waters, Simon
    Poole, Christopher
    Twelves, Chris
    Perren, Timothy
    Bartlett, John
    Piper, Tammy
    Chisholm, Eve Macdonald
    Welsh, Michelle
    Hill, Robert
    Hopcroft, Lisa E. M.
    Barrett-Lee, Peter
    Cameron, David A.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (01) : 35 - 46
  • [3] A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Cristofanilli, M.
    Valero, V.
    Mangalik, A.
    Rabinowitz, I.
    Arena, F. P.
    Kroener, J. F.
    Curcio, E.
    Watkins, C.
    Magill, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
    Ailsa J. Oswald
    Stefan N. Symeonides
    Duncan Wheatley
    Stephen Chan
    Adrian Murray Brunt
    Karen McAdam
    Peter Schmid
    Simon Waters
    Christopher Poole
    Chris Twelves
    Timothy Perren
    John Bartlett
    Tammy Piper
    Eve Macdonald Chisholm
    Michelle Welsh
    Robert Hill
    Lisa E. M. Hopcroft
    Peter Barrett-Lee
    David A. Cameron
    [J]. Breast Cancer Research and Treatment, 2023, 199 : 35 - 46
  • [5] Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer
    Gucalp, Ayca
    Sparano, Joseph A.
    Caravelli, James
    Santamauro, Jean
    Patil, Sujata
    Abbruzzi, Alyson
    Pellegrino, Christine
    Bromberg, Jackie
    Dang, Chau
    Theodoulou, Maria
    Massague, Joan
    Norton, Larry
    Hudis, Clifford
    Traina, Tiffany A.
    [J]. CLINICAL BREAST CANCER, 2011, 11 (05) : 306 - 311
  • [6] Phase II study of the novel oral Src-kinase inhibitor, AZD0530, in previously treated advanced colorectal cancer patients
    Eng, Cathy
    Kopetz, Scott
    Morris, Jeffrey
    Malik, Zulfiqar
    Stewart, David
    Chang, Hsiu-yin
    Ohinata, Aki
    Abbruzzese, James
    Gallick, Gary
    [J]. CANCER RESEARCH, 2008, 68 (09)
  • [7] Fulvestrant plus anastrozole as neoadjuvant therapy in postmenopausal women with hormone receptor positive early breast cancer
    Khan, Q. J.
    Barr, J. A.
    Britt, A. S.
    Kimler, B. F.
    Connor, C. S.
    McGinness, M.
    Mammen, J. M. V.
    Wagner, J. L.
    Amin, A.
    Springer, M.
    Baccaray, S.
    Fabian, C. J.
    Sing, A. P.
    Sharma, P.
    [J]. CANCER RESEARCH, 2016, 76
  • [8] A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Barroso-Sousa, Romualdo
    Krop, Ian E.
    Trippa, Lorenzo
    Tan-Wasielewski, Zhenying
    Li, Tianyu
    Osmani, Wafa
    Andrews, Chelsea
    Dillon, Deborah
    Richardson, Edward T.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Schoenfeld, Jonathan Daniel
    Tolaney, Sara M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR plus ) metastatic breast cancer
    Rampurwala, Murtuza
    Wisinski, Kari B.
    Burkard, Mark E.
    Ehsani, Sima
    O'Regan, Ruth M.
    Carmichael, Lakeesha
    Kim, KyungMann
    Kolesar, Jill
    Tevaarwerk, Amye J.
    [J]. INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 87 - 94
  • [10] ARISTACAT-Aromatase inhibition plus minus saracatinib as advanced breast cancer therapy: A randomised phase II study of aromatase inhibition plus/minus the Src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer
    Cameron, David
    Symeonides, Stefan
    Brunt, Murray
    Schmid, Peter
    Waters, Simon
    Twelves, Christopher
    Barrett-Lee, Peter
    Bartlett, John
    Piper, Tammy
    McAdam, Karen
    Chisholm, Eve Macdonald
    Welsh, Michelle
    Hill, Robert
    [J]. CANCER RESEARCH, 2020, 80 (04)
12345